{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:48:24Z","timestamp":1774291704401,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T00:00:00Z","timestamp":1496016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1038\/aps.2016.174","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T09:01:37Z","timestamp":1496048497000},"page":"1195-1204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients"],"prefix":"10.1038","volume":"38","author":[{"given":"Yu-si","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,29]]},"reference":[{"key":"BFaps2016174_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","volume":"17","author":"AW Thomson","year":"1995","unstructured":"Thomson AW, Bonham CA, Zeevi A . Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17: 584\u201391.","journal-title":"Ther Drug Monit"},{"key":"BFaps2016174_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1756285615571873","volume":"8","author":"JL Cruz","year":"2015","unstructured":"Cruz JL, Wolff ML, Vanderman AJ, Brown JN . The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord 2015; 8: 92\u2013103.","journal-title":"Ther Adv Neurol Disord"},{"key":"BFaps2016174_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1468-1331.2006.01476.x","volume":"13","author":"G Skeie","year":"2006","unstructured":"Skeie G, Apostolski S, Evoli A, Gilhus N, Hart I, Harms L, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006; 13: 691\u20139.","journal-title":"Eur J Neurol"},{"key":"BFaps2016174_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1196\/annals.1405.000","volume":"1132","author":"JM Ponseti","year":"2008","unstructured":"Ponseti JM, Gamez J, Azem J, L\u00f3pez-Cano M, Vilallonga R, Armengol M . Tacrolimus for myasthenia gravis. Ann N Y Acad Sci 2008; 1132: 254\u201363.","journal-title":"Ann N Y Acad Sci"},{"key":"BFaps2016174_CR5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","volume":"82","author":"H Yoshikawa","year":"2011","unstructured":"Yoshikawa H, Kiuchi T, Saida T, Takamori M . Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011; 82: 970\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFaps2016174_CR6","unstructured":"Group of Neuro-Immunity DoN, Chinese Medical Association. Consensus on the treatment and diagnosis of myasthenia gravis in China. Chin J Neuroimmunol Neurol 2011; 18: 386\u201372."},{"key":"BFaps2016174_CR7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bcp.12830","volume":"81","author":"CY Zhao","year":"2016","unstructured":"Zhao CY, Jiao Z, Mao JJ, Qiu XY . External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol 2016; 81: 891\u2013907.","journal-title":"Br J Clin Pharmacol"},{"key":"BFaps2016174_CR8","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/liv.12133","volume":"33","author":"S Beckebaum","year":"2013","unstructured":"Beckebaum S, Cicinnati VR, Radtke A, Kabar I . Calcineurin inhibitors in liver transplantation \u2013 still champions or threatened by serious competitors? Liver Int 2013; 33: 656\u201365.","journal-title":"Liver Int"},{"key":"BFaps2016174_CR9","unstructured":"(FDA) UFaDA. Prograf\u00ae: tacrolimus capsules\/ tacrolimus injection (for intravenous infusion only). ed. Available from http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050708s027,050709s021lbl.pdf [revised May 2009; cited August 2016]."},{"key":"BFaps2016174_CR10","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s40262-016-0396-1","volume":"55","author":"E Brooks","year":"2016","unstructured":"Brooks E, Tett SE, Isbel NM, Staatz CE . Population pharmacokinetic modelling and bayesian estimation of tacrolimus exposure: is this clinically useful for dosage prediction yet? Clin Pharmacokinet 2016; 55: 1295\u2013335.","journal-title":"Clin Pharmacokinet"},{"key":"BFaps2016174_CR11","first-page":"237","volume":"29","author":"P Li","year":"2009","unstructured":"Li P, Liu L, Ma P . Ding Cl, Tong WH, Zhang XF, et al. LC-MS\/MS determination of tacrolimus in human blood and application in its bioequivalence study. Chin J Pharm Anal 2009; 29: 237\u201342.","journal-title":"Chin J Pharm Anal"},{"key":"BFaps2016174_CR12","first-page":"497","volume":"38","author":"KE Osserman","year":"1971","unstructured":"Osserman KE, Genkins G . Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 1971; 38: 497\u2013537.","journal-title":"Mt Sinai J Med"},{"key":"BFaps2016174_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson N . PsN-Toolkit \u2014 a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"key":"BFaps2016174_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, Van Benten M, Beijnen JH, Schellens JH, Huitema AD . Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011; 101: 72\u20139.","journal-title":"Comput Methods Programs Biomed"},{"key":"BFaps2016174_CR15","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03891.x","volume":"71","author":"SB Duffull","year":"2011","unstructured":"Duffull SB, Wright DF, Winter HR . Interpreting population pharmacokinetic pharmacodynamic analyses \u2014 a clinical viewpoint. Br J Clin Pharmacol 2011; 71: 807\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"BFaps2016174_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentr\u00e9 F . Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154\u201366.","journal-title":"Comput Methods Programs Biomed"},{"key":"BFaps2016174_CR17","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1038\/psp.2013.26","volume":"2","author":"W Byon","year":"2013","unstructured":"Byon W, Smith M, Chan P, Tortorici M, Riley S, Dai H, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol 2013; 2: e51.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"BFaps2016174_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF01059771","volume":"21","author":"JR Wade","year":"1993","unstructured":"Wade JR, Kelman AW, Howie CA, Whiting B . Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm 1993; 21: 209\u201322.","journal-title":"J Pharmacokinet Biopharm"},{"key":"BFaps2016174_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/jlts.2003.50023","volume":"9","author":"CE Staatz","year":"2003","unstructured":"Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE . Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 2003; 9: 130\u20137.","journal-title":"Liver Transpl"},{"key":"BFaps2016174_CR20","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1067\/mcp.2002.129304","volume":"72","author":"CE Staatz","year":"2002","unstructured":"Staatz CE, Willis C, Taylor PJ, Tett SE . Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 72: 660\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps2016174_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1600-0404.1984.tb00817.x","volume":"70","author":"H Hofstad","year":"1984","unstructured":"Hofstad H, Ohm OJ, M\u00f8rk SJ, Aarli JA . Heart disease in myasthenia gravis. Acta Neurol Scand 1984; 70: 176\u201384.","journal-title":"Acta Neurol Scand"},{"key":"BFaps2016174_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijcme.2014.08.003","volume":"5","author":"P Shivamurthy","year":"2014","unstructured":"Shivamurthy P, Parker MW . Cardiac manifestations of myasthenia gravis: A systematic review. IJC Metab Endocr 2014; 5: 3\u20136.","journal-title":"IJC Metab Endocr"},{"key":"BFaps2016174_CR23","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1056\/NEJM197805252982102","volume":"298","author":"RA Zito","year":"1978","unstructured":"Zito RA, Reid PR . Lidocaine kinetics predicted by indocyanine green clearance. N Engl J Med 1978; 298: 1160\u20133.","journal-title":"N Engl J Med"},{"key":"BFaps2016174_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJM197107292850506","volume":"285","author":"MM Reidenberg","year":"1971","unstructured":"Reidenberg MM, Odar-Cederl\u00f6f I, von Bahr C, Borg\u00e5 O, Sj\u00f6qvist F . Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med 1971; 285: 264\u20137.","journal-title":"N Engl J Med"},{"key":"BFaps2016174_CR25","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/0006-2952(76)90370-1","volume":"25","author":"I Sj\u00f6holm","year":"1976","unstructured":"Sj\u00f6holm I, Kober A, Odar-Cederl\u00f6f I, Borg\u00e5 O . Protein binding of drugs in uremic and normal serum: The role of endogenous binding inhibitors. Biochem Pharmacol 1976; 25: 1205\u201313.","journal-title":"Biochem Pharmacol"},{"key":"BFaps2016174_CR26","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1021\/bi00879a032","volume":"4","author":"GR Stark","year":"1965","unstructured":"Stark GR . Reactions of cyanate with functional groups of proteins. II. Formation, decomposition, and properties of N-carbamylimidazole*. Biochemistry 1965; 4: 588\u201395.","journal-title":"Biochemistry"},{"key":"BFaps2016174_CR27","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1016\/S0021-9258(20)81332-5","volume":"235","author":"GR Stark","year":"1960","unstructured":"Stark GR, Stein WH, Moore S . Reactions of the cyanate present in aqueous urea with amino acids and proteins. J Biol Chem 1960; 235: 3177\u201381.","journal-title":"J Biol Chem"},{"key":"BFaps2016174_CR28","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/clpt.1980.87","volume":"27","author":"S Erill","year":"1980","unstructured":"Erill S, Calvo R, Carlos R . Plasma protein carbamylation and decreased acidic drug protein binding in uremia. Clin Pharmacol Ther 1980; 27: 612\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps2016174_CR29","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1208\/s12248-015-9793-x","volume":"17","author":"CV Lagishetty","year":"2015","unstructured":"Lagishetty CV, Duffull SB . Evaluation of approaches to deal with low-frequency nuisance covariates in population pharmacokinetic analyses. AAPS J 2015; 17: 1388\u201394.","journal-title":"AAPS J"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps2016174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2016174","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/aps.2016.174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/aps2016174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:50:22Z","timestamp":1692820222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps2016174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,29]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["BFaps2016174"],"URL":"https:\/\/doi.org\/10.1038\/aps.2016.174","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,29]]},"assertion":[{"value":"25 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}